Posted February 14, 2020
SEC filings reveal that Merck’s Vaccine Division President Julie Gerberding sold over half her Merck shares in January for $9.1 Million. That transaction followed a spate of bad news for Merck’s flagship Gardasil vaccine. Last month, Cancer Research UK announced an alarming 54% rise in cervical cancer among 24-29-year-olds, the first generation to receive the HPV jabs. The following day, the Journal of the Royal Society of Medicine published a withering critique of Gardasil’s crooked clinical trials. Read more.